Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q4JM
|
||||
| Former ID |
DNCL002183
|
||||
| Drug Name |
TAK-441
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1], [2] | ||
| Company |
Millennium Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H31F3N4O6
|
||||
| InChI |
InChI=1S/C28H31F3N4O6/c1-3-19-13-20-23(27(40)35(19)14-21(37)17-7-5-4-6-8-17)25(41-16-28(29,30)31)24(33(20)2)26(39)32-18-9-11-34(12-10-18)22(38)15-36/h4-8,13,18,36H,3,9-12,14-16H2,1-2H3,(H,32,39)
|
||||
| InChIKey |
ZADWXQMNNVICKB-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | smoothened receptor | Target Info | Modulator | [3] | |
| KEGG Pathway | Hedgehog signaling pathway | ||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| Basal cell carcinoma | |||||
| PANTHER Pathway | Hedgehog signaling pathway | ||||
| Pathway Interaction Database | Signaling events mediated by the Hedgehog family | ||||
| Hedgehog signaling events mediated by Gli proteins | |||||
| Reactome | Class B/2 (Secretin family receptors) | ||||
| Hedgehog 'off' state | |||||
| Activation of SMO | |||||
| WikiPathways | Hedgehog Signaling Pathway | ||||
| Hair Follicle Development: Organogenesis (Part 2 of 3) | |||||
| Hair Follicle Development: Induction (Part 1 of 3) | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| GPCR ligand binding | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01204073) A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8200). | ||||
| REF 3 | TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955-66. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.